Vitruvias Therapeutics is recalling one lot of nationwide thyroid medication due to testing results indicating the pills possess higher potency than intended, based upon a recall announcement issued by the U.S. Food and Drug Administration (FDA). The firm located in Auburn, Alabama, has initiated a voluntary consumer-level recall for Lot 504950 of Thyroid Tablets, USP 30 mg owing to potential superpotency hazards.
Vitruvias Therapeutics Recall Details and Affected Lot Numbers
The voluntary recall impacts 3,655 total units released to the market, with 1,955 units sold before the action was initiated. According to FDA records, the affected medication carries NDC 69680-166-00 and an expiration date of Sept. 30, 2026. Vitruvias Therapeutics distributed the impacted lot nationwide to direct accounts between Jan. 31, 2025, and Sept. 30, 2025.
Did you know?
Thyroid, USP is derived from porcine thyroid glands and contains levothyroxine and liothyronine. The medication is used to treat hypothyroidism, or an underactive thyroid.
Health Risks Associated With Superpotent Thyroid Medication
Taking superpotent thyroid tablets can trigger hyperthyroidism, or an overactive thyroid. Based on information provided by Vitruvias Therapeutics, adverse signs of elevated thyroid hormone levels comprise weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances.
Certain patient populations face heightened clinical risks from extended exposure to excessive hormone levels. Elderly patients, pregnant women, and infants are particularly vulnerable. Excess thyroid hormone links directly to cardiac problems in older adults. Overtreatment during pregnancy associates with premature delivery and low birth weight, while infant exposure may negatively impact normal growth and development.
What Patients and Wholesalers Should Do Next
Vitruvias Therapeutics confirmed it has received no reports of adverse events connected to the recall. Wholesalers must stop distributing the recalled product and arrange for its destruction, according to company instructions.
Individuals currently taking pills from the impacted batch ought to consult their healthcare professional prior to halting the treatment, ensuring they obtain proper advice or a substitute prescription. A representative for Vitruvias Therapeutics did not immediately respond to FOX Business requests for additional information.
Pro tip for consumers:
Consumers with questions can contact Vitruvias Therapeutics directly at [email protected] or by calling 256-239-9373. Anyone experiencing adverse symptoms should contact a physician immediately.
Frequently Asked Questions
What specific product is being recalled by Vitruvias Therapeutics?
The company is recalling one lot of Thyroid Tablets, USP 30 mg, designated as Lot 504950 with NDC 69680-166-00 and an expiration date of Sept. 30, 2026.
Why is the thyroid medication being recalled?
Testing found that the tablets could be more potent than intended, posing a risk of superpotency that can lead to hyperthyroidism.
Should I stop taking my thyroid medication immediately?
Who should I contact if I have adverse reactions or questions?
You can reach Vitruvias Therapeutics at [email protected] or 256-239-9373. Consult a physician or healthcare provider if you experience any problems connected to the medication.
Keep reading